H.R.1, One Big Beautiful Bill Act, all bio-pharmaceutical related provisions.
Literal federal measure citations: H.R.1
Source-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 20, 2026
- Income
- Not reported
- Expenses
- $710,000.00
- Registrant
- EISAI INC.
- Client
- EISAI INC.
- Filing UUID
- 39505573-53b1-485e-8a01-a9724c9d30e6
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; pharmaceutical scheduling; PBM reform; S.891, Bipartisan Health Care Act, improvements to the 340B drug discount program; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
Literal federal measure citations: S.891
General issues related to Medicare and Medicaid, including: Part D Medicare Program; drug pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation. Issues related to pharmaceutical intellectual property; HR 6130 / S 3267, the ASAP Act; legislation pertaining to cognitive assessments in Medicare.
Issues related to tax reform; R&D tax credit; Section 899; H.R.1, One Big Beautiful Bill Act.
Literal federal measure citations: H.R.1
Issues related to supply chain and tariffs. Section 232 tariff investigation on branded pharmaceuticals.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.